Preferred Label : Anti-NKG2A Monoclonal Antibody BRY805;
NCIt definition : A humanized monoclonal antibody against the human natural killer (NK) and T-lymphocyte
cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A;
natural killer group 2 A), with potential antineoplastic activity. Upon administration,
anti-NKG2A monoclonal antibody BRY805 targets and binds to NKG2A, thereby preventing
the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed
on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating
NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response
against cancer cells leading to their destruction. Human NKG2A, an inhibitory cell
surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation
of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a
nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated
with poor prognosis.;
Molecule name : BRY-805; BRY 805;
Origin ID : C211549;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
